Mutations in the X region and core promoter are rare and have little impact on response to interferon therapy for chronic hepatitis B

Journal of Medical Virology

Volumn 66, Issue 2, 2002, Pages 171-178

  Hannoun, Charles ^a   Horal, Peter ^b   Krogsgaard, Kim ^c   Lindh, Magnus ^a,c  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b HVIDOVRE HOSPITAL   (Denmark)

^c Guldhedsgatan 10B ^*  (Sweden)

Author keywords

Genotype; Hepatitis B virus; Interferon; Mutation; Response

Indexed keywords

ALPHA INTERFERON; AMINOTRANSFERASE; HEPATITIS B(E) ANTIGEN;

ADULT; AMINO ACID SUBSTITUTION; ARTICLE; CLINICAL ARTICLE; CONSENSUS SEQUENCE; CONTROLLED STUDY; FEMALE; GENE MUTATION; GENETIC VARIABILITY; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; IMMUNE RESPONSE; MALE; NUCLEIC ACID BASE SUBSTITUTION; NUCLEOTIDE SEQUENCE; PHYLOGENY; POLYMERASE CHAIN REACTION; PROMOTER REGION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SEQUENCE ANALYSIS; SEROCONVERSION; X CHROMOSOME;

ADULT; AMINO ACID SEQUENCE; ANTIVIRAL AGENTS; DNA, VIRAL; FEMALE; GENOTYPE; HEPATITIS B CORE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MUTATION; PHYLOGENY; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; PROMOTER REGIONS (GENETICS); SEQUENCE ANALYSIS, DNA; TRANS-ACTIVATORS; TREATMENT OUTCOME;

HEPATITIS B VIRUS;

EID: 0036137092     PISSN: 01466615     EISSN: None     Source Type: Journal    
DOI: 10.1002/jmv.2127     Document Type: Article

References (26)

1. Which patients with chronic hepatitis B virus infection will respond to alpha-interferon therapy? A statistical analysis of predictive factors
2. Hepatitis B virus unable to secrete e antigen and response to interferon in chronic hepatitis B
3. Effects of a naturally occurring mutation in the hepatitis B virus basal core promoter on precore gene expression and viral replication
4. Mutations of the core promoter and response to interferon treatment in chronic replicative hepatitis B
5. Hepatitis B virus precore/core variation and interferon therapy
6. Frequent and rapid emergence of mutated pre-C sequences in HBV from e-antigen positive carriers who seroconvert to anti-HBe during interferon treatment
7. Wild-type levels of pregenomic RNA and replication but reduced pre-C RNA and e-antigen synthesis of hepatitis B virus with C(1653) → T, A(1762) → T, and G(1764) → A mutations in the core promoter
8. Long-term mutation rates in the hepatitis B virus genome
9. Detection of mutations in the enhancer 2/core promoter region of hepatitis B virus in patients with chronic hepatitis B virus infection: Comparison with mutations in precore and core regions in relation to clinical status
10. T1762/ A1764 variants of the basal core promoter of hepatitis B virus; serological and clinical correlations in Chinese patients
11. Prednisolone withdrawal therapy enhances the effect of human lymphoblastoid interferon in chronic hepatitis B
12. MEGA: Molecular evolutionary genetics analysis software for microcomputers
13. Hepatitis B virus core promoter sequence analysis in fulminant and chronic hepatitis B
14. Genotypes, nt 1858 variants, and geographic origin of hepatitis B virus-large-scale analysis using a new genotyping method
15. Mutation of nucleotide 1762 in the core promoter region during hepatitis B e seroconversion and its relation to liver damage in hepatitis B e antigen carriers
16. Core promoter mutations and genotypes in relation to viral replication and liver damage in East Asian hepatitis B virus carriers
17. Virological response to interferon theraphy of chronic hepatitis B as measured by a highly sensitive assay
18. Natural history and control of perinatally acquired hepatitis B virus infection
19. Predictive value of precore hepatitis B virus mutations in spontaneous and interferon-induced hepatitis B e antigen clearance
20. Reduced precore transcription and enhanced core-pregenome transcription of hepatitis B virus DNA after replacement of the precore-core promoter with sequences associated with e antigen-seronegative persistent infections
21. Long-term follow-up of HBeAg-positive patients treated with interferon alpha for chronic hepatitis B
22. Hepatitis B virus with mutations in the core promoter for an e antigen-negative phenotype in carriers with antibody to e antigen
23. A randomized, controlled trial of interferon alpha-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B
24. The clinical significance of core promoter and precore mutations during the natural course and interferon therapy in patients with chronic hepatitis B
25. 1764) of hepatitis B virus: Clinical significance and an easy method for detection
26. Analysis of hepatitis B virus genotypes and pre-core region variability during interferon treatment of HBe antigen negative chronic hepatitis B